Geron Corporation
NASDAQ:GERN
Overview | Financials
Company Name | Geron Corporation |
Symbol | GERN |
Currency | USD |
Price | 3.49 |
Market Cap | 2,109,708,490 |
Dividend Yield | 0% |
52-week-range | 1.64 - 5.34 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. John A. Scarlett M.D. |
Website | https://www.geron.com |
An error occurred while fetching data.
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD